ArticleJAMA network open2020
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis.Journal of general internal medicine · 2022Pooled it
- Nutrient-dependent hippocampus dopamine signaling enhances meal-related episodic memory and reduces food intake.bioRxiv : the preprint server for biology · 2026Article
- Analyzing longitudinal antidiabetic medication patterns: a data-driven clustering framework.BMC medical informatics and decision making · 2026Article
- Case study on adverse reactions of dulaglutide: literature review.Frontiers in pharmacology · 2026Article
- Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Association Between Therapeutic Inertia and Future Hypoglycemia Among Patients with Type 2 Diabetes.Diabetes epidemiology and management · 2026Article
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.JAMA network open · 2025Article
- Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes.Journal of managed care & specialty pharmacy · 2025Article
- Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.The Journal of clinical endocrinology and metabolism · 2025 · on this mapReview
- Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.American heart journal · 2025Article
- Prescriber Uptake and Use of Novel Lipid-Lowering Therapies.Journal of the American Heart Association · 2025Article
- Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure.Circulation. Heart failure · 2025Article
- SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study.Journal of diabetes research · 2025Article
- A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?Surgical endoscopy · 2024Article
- Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.Journal of general internal medicine · 2024Article
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Finerenone: Who should prescribe it for CKD? The physician associate's perspective.Journal of nephrology · 2024Review
- Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.BMC cardiovascular disorders · 2024Article
- Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020.American journal of preventive cardiology · 2024Article
- Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.Current medical research and opinion · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.